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Patch angioplasty is commonly performed after carotid endarterectomy. Randomized prospective trials andmeta-analyses
have documented improved rates of perioperative and long-term stroke prevention as well as reduced rates of restenosis
for patches compared with primary closure of the arteriotomy. Although use of vein patches is considered to be the gold
standard for patch closure, newer generations of synthetic and biologic materials rival outcomes associated with vein
patches. Future bioengineered patches are likely to optimize patch performance, both by achieving minimal stroke risk
and long-term rates of restenosis as well as by minimizing the risk of unusual complications of prosthetic patches such as
infection and pseudoaneurysm formation. In addition, lessons from bioengineered patches will likely enable construction
of bioengineered and tissue-engineered bypass grafts. ( J Vasc Surg 2009;50:206-13.)Since surgical repair of symptomatic carotid artery ste-
nosis was first reported by Eastcott et al1 in 1954, carotid
artery endarterectomy (CEA) has remained the standard
management strategy for significant carotid stenosis in both
symptomatic and asymptomatic patients. Approximately
100,000 CEAs are performed annually in the United
States.2-4
The standard surgical approach for CEA involves a
longitudinal arteriotomy from the common to the internal
carotid artery, allowing plaque removal. Unfortunately,
closure of the longitudinal arteriotomy also allows for the
possibility of narrowing the artery, either immediately or in
delayed fashion, thus mimicking the stenosis for which the
surgery was originally performed. Closure of the arteriot-
omy with a patch minimizes the effect of neointimal hyper-
plasia and scarring and maintains the arterial lumen diam-
eter after the procedure. In addition, patches are commonly
used to close arteriotomies in other vascular beds, such as
after common femoral endarterectomy or profundaplasty.
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206Eversion endarterectomy is an alternative surgical tech-
nique that allows plaque removal without longitudinal
arteriotomy and potentially avoids placement of a patch;
however, this technique is less frequently practiced.
To avoid restenosis after CEA, carotid patching was
routinely used by Imparato5 as early as 1965, and many
articles have since supported the use of a patch.6-11 Another
early advocate of vein patching after CEA was Dr Thor
Sundt, who was also a pioneer in his laboratory investiga-
tions examining the healing of carotid patches in a dog
model.12 Recent reviews continue to highly recommend
patch angioplasty after CEA to avoid restenosis compared
with primary arterial closure.13 Patching is now thought to
be part of optimal care of the patient undergoing traditional
CEA.14,15 In this review, we describe traditional and novel
patch materials and review the characteristics and clinical
results of these patches.
WHY PATCH AT ALL?
Important factors for all successful surgical procedures
include simplicity, ease, safety, short duration, and cost-
effectiveness. As such, primary closure for CEA can be seen
as a good choice, with patch closure being somewhat more
complicated and of longer duration. Therefore, it is a valid
question to ask whether patching after CEA is a reasonable
activity at all.
In 2004 Bond et al10,11 reviewed the outcome of seven
randomized trials comprising 1281 procedures in which
primary closure was compared with patch angioplasty after
CEA. Patch angioplasty was associated with reduced 30-
day risk of ipsilateral stroke (1.6% vs 4.8%, P  .001),
reduced risk of stroke or death (2.5% vs 6.1%, P  .007),
reduced rates of return to surgery (1.1% vs 3.1%, P  .01),
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.0001) compared with primary closure. In addition, carotid
patching was associated with reduced long-term rates of
ipsilateral stroke (1.6% vs 4.8%, P  .001), reduced risk of
stroke or death (14.6% vs 24.1%, P  .004), and reduced
rates of recurrent stenosis (4.8% vs 18.6%, P  .0001)
compared with primary closure.
This meta-analysis provides strong evidence that ca-
rotid patching provides both perioperative and long-term
benefits for patient care and is consistent with standard use
of patching during CEA. The benefit that is probably the
most generally agreed upon is the reduced rate of restenosis
in the long-term. Several important series are reviewed in
Table I.16-23 Although these series are heterogeneous, and
reflect different patch materials and times of follow-up, the
data nevertheless show that placement of a carotid patch is
associated with fewer strokes and less restenosis compared
with primary arterial closure.
Other accepted indications for patch angioplasty after
CEA traditionally include a very small internal carotid
artery (4 mm), an extended, complex, or irregular arteri-
otomy, and concomitant repair of a distal internal carotid
artery that contains a kink or coil. Patching may allow
optimization of blood flow, vessel geometry, and biome-
chanics, although the influence of these physical parameters
on long-term patient outcome is not well described.
TYPES OF PATCHES
The ideal requirements for any patching material are
summarized in Table II. The following sections describe a
variety of materials that are in common use for arteriotomy
closure during CEA, each with advantages and disadvan-
tages.
Prosthetic patches. The most commonly used pros-
thetic patching materials are polytetrafluoroethylene
(PTFE) and Dacron. PTFE is a fluoride resin composed of
only carbon and fluoride. Expanded PTFE (ePTFE) has a
porous structure with 20- to 30-m fibril distance and is
also commonly used as a vascular graft. It has properties
that include resistance to thrombosis and the ability to
support re-endothelialization. More recently, an elasto-
Table I. Improved outcome after patch closure compared
Number
Study
First author, y Primary Patch
Hertzer,16 1987 483 434
Ranaboldo,17 1993 104 109
AbuRahma,18 1996 135 264
Katras,19 2001 97 107
Ali,20 2005 117 119
Rockman,21 2005 233 1377
Verhoeven,22 2005 83 236
Hertzer,23 2006 783 1479
aTime and degree of restenosis were defined by the authors of the referencemeric coating such as polyurethane has been applied to theoutside surface of ePTFE patches to minimize suture hole
bleeding.24
Dacron is a polyester fiber, a condensation polymer of
ethylene glycol and terephthalic acid, and shows high ten-
sile strength and resistance to stretching. Woven or knitted
sheets of Dacron are commonly used in vascular surgery,
including use as vascular grafts.
An early Italian trial first showed the importance of
prosthetic patch angioplasty in preventing restenosis after
carotid endarterectomy.25 Prosthetic patches have a signif-
icant advantage because they are ready-to-go (ie, available
by just opening the package). In addition, outcomes of
recent generations of various prosthetic materials show no
differences compared with autologous vein patches.26-28
For example, Naylor et al28 reviewed the Leicester experi-
ence with 269 patients randomized to vein or thin-walled
Dacron (Hemashield Finesse, Boston Scientific, Natick,
Mass) patch closure. After 3 years, cumulative freedom
from death or ipsilateral stroke was 93.0% in the Dacron-
patched group compared with 95.5% in the vein-patched
group (P  .42). Interestingly, cumulative freedom from
recurrent stenosis (70%) was 92.9% in the Dacron-
patched group compared with 98.4% in the vein-patched
group (P  .03).28
Similar results were reported from the ClevelandClinic,
with synthetic and vein patches having similar low rates of
late stroke (2.1% vs 2.0%) and slightly higher but not
statistically significant incidence of restenosis (60%) in
synthetic patches compared with vein patches (6.3% vs
4.8%, P  .99).27 A recent Cochrane review suggested an
primary closure after carotid endarterectomy
Stroke, % Restenosis, %a
Primary Patch Primary Patch
3.1 0.7 31 9
5.8 1.8 16 6
5.2 1.5 12 3
2.8 1.0 9 6
7.7 1.7 25 7
5.6 2.2 . . . . . .
6.0 2.5 11 7
2.8 1.4 29 15
y.
Table II. Ideal requirements for a carotid patch material
● Long-term stability and durability
● Low risk of restenosis
● Compliance near that of the host artery
● Comfortable handling characteristics
● Easy harvest or ready to use
● Anticoagulant function
● Resistance to infection and late degenerationwithodds ratio for risk of restenosis of 1.34 for PTFE patches
d stud
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interval (CI) of 0.71 to 2.51.29
Although PTFE patches were originally very com-
monly used for CEA, collagen-impregnated Dacron
patches became more commonly used upon recognition of
their advantage in hemostatic function (ie, reduced bleed-
ing from the suture holes).13 Carney et al30 reported that
PTFE patches showed significantly longer time to attain
hemostasis after release of the clamps at the end of the
operation, an increased incidence of blood loss 300 mL,
and greater use of oxidized cellulose to stop the bleeding
compared with vein or Dacron patches. In addition,
AbuRahma et al31 reported significantly longer hemostasis
times in PTFE-patched patients compared with Dacron-
patched patients (14.4 vs 3.4minutes, P .001). This group
also reported that the long-term results of older collagen-
impregnated Dacron patches compared unfavorably with
ePTFE, with higher rates of postoperative stroke (7% vs 0%,
P  .02) and carotid restenosis (12% vs 2%, P  .013).
Recent newer developments include sealing ePTFE
patches (ACUSEAL; W. L. Gore & Assoc, Flagstaff, Ariz)
and less thrombogenic Dacron patches (Hemashield Fi-
nesse), with each generation attempting to improve upon
previous versions; for example, hemostasis times are typi-
cally shorter (3 to 4 minutes) and comparable between
materials. AbuRahma et al32 recently reported no signifi-
cant differences in perioperative stroke (2% vs 2%, P .99)
and short-term restenosis risk (0% vs 4%, P .12) between
these patches. These results were recently confirmed in
longer-term follow-up, with cumulative stroke-free rates of
98% for ePTFE and 97% for Dacron at 3 years (P  .7),
whereas cumulative freedom from restenosis (70%) was
89% for ePTFE and 79% for Dacron at 3 years (P .04).33
In a recent Cochrane review, ePTFE and Dacron
patches showed similar rates of arterial restenosis and oc-
clusion compared with vein patches (OR, 1.01; 95% CI,
0.61-1.66).29 Several large series have suggested increased
rates of restenosis in Dacron patches (Table III).18,28,33-36
It is likely that as additional materials are made available for
clinical use, the results of these two prosthetic materials will
converge. We believe that one advance in the reduction of
bleeding time that is traditionally associated with ePTFE
Table III. Outcome after patch closure–effects of differen
Number
Study
First author, y Vein Dacron ePTFE V
AbuRahma,18 1996 130 . . . 134
Archie,34 2000 903 359 27
Jacobowitz,35 2001 159 90 . . .
Grego,36 2003 80 . . . 80
Naylor,28 2004 134 133 . . .
AbuRahma,33 2008 . . . 100 100
ePTFE, Expanded polytetrafluoroethylene.
aTime and degree of restenosis were defined by the authors of the referencepatches is the use of superiorly swagged needles, with theneedle diameter not significantly larger than the suture
diameter, creating less empty space for bleeding around
the suture. Thus, time to hemostasis may be less patch-
dependent with the use of newer sutures and needles.
Other significant long-term sequelae associated with
prosthetic patches include pseudoaneurysm formation and
development of infection.37,38 Although both complica-
tions are unusual but treatable, this certainly suggests that
use of prosthetic patch materials may require life-long
surveillance in susceptible populations and thus are clearly
not perfect materials. In particular, the rates of infection are
unfavorably higher compared with other materials and
remain as a point of improvement for future developments.
An early report by Branch and Davis39 linked infection
and pseudoaneurysm formation after CEA. This review of
57 cases estimated an incidence of 0.30% of pseudoaneu-
rysm after CEA and estimated that CEA performed with
primary closure had half this rate of postoperative infec-
tion.39 One of the largest series of prosthetic patch infec-
tions was described by Cooley’s group at the Texas Heart
Institute.40 This report of 13 cases of patch infections
associated with pseudoaneurysms discussed a number of
points from this group’s extensive experience that remain
critical for optimal patient management:
● Infection complicates patches, both prosthetic and
vein, more frequently than primary arterial closures.
● Braided sutures such as silk can trap bacteria in their
interstices, providing a nidus of infection in earlier
series; the use of monofilament sutures, especially
polypropylene, has eliminated this risk.
● Untreated patch infection can lead to patch blowout
and massive hemorrhage, as well as sepsis, abscess
formation, or stroke; these presentations must be
treated urgently.
● Staphylococcus species were the most commonly cul-
tured organism (29 of 30 patients), followed by gram-
negative rods (7 of 30 patients).
● Surgical repair involves extensive dissection and usu-
ally needs general anesthesia.
● Use of a shunt is desirable but potentially hazardous
ch materials
Stroke, % Restenosis, %a
Dacron ePTFE Vein Dacron ePTFE
. . . 2.2 2.9 . . . 2.2%
6.4 3.7 . . . . . . . . .
2.2 . . . 2.2 8.5 . . .
. . . 6.4 9.3 . . . 13.3
7 . . . 1.6 7.1 . . .
3 2 . . . 21 11
y.t pat
ein
0.8
0.6
2.0
1.3
4.5
. . .due to the friable tissues and is usually impractical.
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primary closure; 75% of the patients treated by reclo-
sure of the arteriotomy required early reoperation or
died.
● Most repairs were treated by resection and saphenous
vein replacement; treatment with autogenous tissue is
thought to be mandatory in the presence of gross
infection.
● Minor infections and pseudoaneurysms not associated
with infection may be treated with partial aneurysmec-
tomy and patch repair, although even saphenous vein
patches can be reinfected.
● Ten percent of patients so treated developed postop-
erative strokes or died, most commonly patients need-
ing carotid artery ligation (50%) and least frequently in
patients in whom repeat patch placement was possible
(12%).
● Recurrent patch infection was common in patients
receiving Dacron patches.
● Donor vein site infection was also possible.
● Cranial nerve injury was less common in these proce-
dures compared with primary CEA.
This series also estimated that infected patches and
pseudoaneurysms occur in 0.18% of CEA.40 A more recent
review of prosthetic patch infections has estimated that
patch infection occurs in approximately 0.37% of all pa-
tients, ranging from 0.26% to 0.71% in several reported
series.38 Repair of these prosthetic patch infections is asso-
ciated with increased morbidity compared with the primary
CEA procedure. Although the reported postoperative mor-
tality rate was 2.6%, the postoperative stroke rate was 2.6%,
the rate of cranial nerve injury was 12.8%, and the rate of
recurrent infection was 7.7%, all of which were greater than
rates associated for elective repair.38 General recommenda-
tions from this group included reconstruction with a vein
patch or an interposition graft, depending on the quality of
the remaining artery after removal of all prosthetic and
infection. The use of a muscle flap to cover the site has been
reported,41 although it is not possible to determine from
the few overall number of case reports whether this adjunc-
tive technique is popular or not.
Venous patches. Patching with autologous venous
tissue remains the most commonly used option for arterial
patching during CEA and continues to show superb results
in the literature (Table III). This patch continues to enjoy
popularity with surgeons: It is commonly used, has excel-
lent handling, and is resistant to thrombosis and restenosis
due to its endothelial lining on the luminal surface.42 Many
reports have compared results of CEA after use of autolo-
gous or synthetic patches.6,11,13,27,29,35Most analyses have
shown no significant differences in early outcomes when
comparing venous with prosthetic patches, with very low
risk of any events.
O’Hara27 reported the results from the Cleveland
Clinic study that randomized 207 patients to vein or syn-
thetic patch closure. The stroke rate in the vein patch group
was 3.0% compared with 2.1% in the synthetic patch group(P  .99). Recurrent stenosis (60%) was present in 4.8%
of the vein patch group compared with 6.3% of the syn-
thetic patch group (P  .99).27 Similarly, Jacobowitz et
al35 reported the New York University experience. In 159
vein patches compared with 90 Dacron patches, similar
rates were found for perioperative stroke (vein 1.3% vs
Dacron 1.1%, PNS) and late stroke (vein 2.0% vs Dacron
2.2%, P  NS). Restenosis of 50% to 79% was present in
2.2% of vein patches and 8.5% of Dacron patches (PNS).
It is of interest that autologous vein was the first mate-
rial to be used for CEA patching. Imparato andWeinstein43
were early proponents for vein patches to be used routinely
to prevent restenosis. Originally, surgeons used the proxi-
mal saphenous vein in the thigh, but patients and surgeons
objected to the additional incision in the thigh for an
operation that should be confined to the neck. This prefer-
ence to avoid proximal saphenous vein harvest led to use of
the distal saphenous vein at the ankle or the cervical veins
harvested within the CEA incision. There was concern that
these veins were weaker and could potentially lead to a
catastrophic blowout.44-48 Some authors have shown that
veins 3.5 mm diameter are generally safe to use with
reduced risk of rupture.49,50
A clever development deployed everted cervical vein
(external jugular or facial vein), thereby creating a double-
walled vein patch with increased tensile strength compara-
ble with the saphenous vein. Because cervical veins are
harvested within the CEA operative field, the additional leg
incision is obviated.51 The double-layered everted cervical
vein patch has demonstrated durable outcomes compared
with the traditional saphenous vein patch.52
Another option is the cryopreserved homograft saphe-
nous vein patch. Plestis et al53 reported a series of 1006
consecutive CEAs repaired with saphenous vein segments
that were harvested from coronary artery bypass procedures
and cryopreserved in 10% dimethyl sulfoxide at –120°C.
Results were excellent, with 1.2% perioperative strokes and
a 10-year cumulative freedom of 96% from ipsilateral
stroke. Recurrence of severe (75%) stenosis was 2%, and
freedom from 20% restenosis was 84% at 10 years. These
results suggest that modified vein may be a durable substi-
tute for autologous vein.
There are few reports of infection after vein patch
placement. In an early series, Thompson54 reported no
cases of vein patch infection in 1140 CEAs, although
pseudoaneurysms occurred in seven Dacron patches (0.6%)
in the series. A notable case report of a vein patch infection
reported repair with resection, segmental replacement with
a vein graft, topical irrigation for 2 weeks, and systemic
antibiotics for 3 weeks.55 Yamamoto et al56 reported their
experience with 2888 CEA closed with vein patches at the
Mayo Clinic in 23 years; only three cases of infection
occurred, all of which involved Dacron or Teflon mesh
reinforcement of the site, without involvement of the vein
patch itself. These were treated with removal of the syn-
thetic material, without disturbance of the vein patch. This
group also reported five patch ruptures of uninfected vein
patches, three of which led to death or severe disability, and
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Interestingly, the group concluded that use of a synthetic
material was preferable to a vein patch.56
Biomaterial patches. Bovine pericardium has served
for many years as a popular option as a biomaterial patch for
CEA.57,58 Kim et al59 reported their preliminary experi-
ence with this patch for CEA, with little differences in
outcome compared with vein patches (no early strokes,
50% restenosis 3.3% vs 1.6%, PNS). Hines et al58 have
recently confirmed these results, with excellent handling
and early results;50% restenosis occurred in 25% of cases
by 2 years, but 16% of cases had 50% to 79% restenosis, and
no cases were detected with 80% restenosis.
Bovine pericardium offers the benefits of off-the-shelf
availability, durability, and biocompatibility, as well as the
ability to ultrasound through the patch immediately after
placement. In addition, the satisfactory use of bovine peri-
cardial patches in infected fields has been reported. How-
ever, bovine pericardium has had reduced popularity after
reports in the lay press of bovine spongiform encephalopa-
thy in certain cattle herds, although bovine spongiform
encephalopathy has never been reported after placement of
a carotid patch.
When compared with outcomes after the use of poly-
ester patches, bovine pericardial patches show comparable
results but may have a lower incidence of recurrent stenosis.
One study reported 4% restenosis in bovine patches com-
pared with 7.6% restenosis in polyester patches, although
the mean length of follow-up in the groups (bovine, 12
months; polyester, 24.5 months) was not comparable.60
Just as the newer prosthetic patches and standard vein
patches show no significant differences regarding durability
and outcomes, it is likely that bovine pericardial patches are
also equivalent. Bovine pericardial patches have shown
significantly decreased intraoperative suture line bleeding
compared with prosthetic patches.61 Although no reports
have compared bovine pericardium with other conduits
regarding rates of postoperative infection, bovine pericar-
dium has been used in other infected cardiovascular
fields.62,63 The low risk of infection after autologous vein
and biomaterial patches may be an important factor for the
future development of tissue engineered vascular patches,
although this assertion also awaits confirmation in large
series.
One other biomaterial that has been reported after use
in an animal study is a combination patch, with one side of
the patch constructed from glutaraldehyde-fixed bovine
peritoneum/fascia and the other side constructed from
polyester.64 This interesting patch was tested in femoral
arteries of dogs, and at 6 months had no degeneration and
complete re-endothelialization; the mechanical strength
was superior to that of bovine pericardial patches. Other
biomaterials for potential use include amnion,65 decellular-
ized bovine inferior vena cava,66 and decellularized human
pericardium.67 Decellularized venous patches have similar
burst and suture-holding strength as native veins.68 As the
tissue-engineering field matures, additional biomaterials
for use as a carotid patch can be expected, such as patcheswith textured surfaces that promote cell migration and
tissue healing.69
FUTURE DIRECTIONS
As excellent results are currently being obtained with
available patch materials, directions for future development
may lie in the prevention of unusual complications such as
infection and pseudoaneurysm. However, additional bene-
fits may become evident as the field develops.
An interesting option for carotid patching was reported
by Jenkins et al70 in which they used the superior thyroid
artery. Use of this autologous vessel has the advantages of
excellent material strength, reduction of surgical cost and
possibly infection risk, excellent compliance match to the
host artery, and availability within the operative field. The
superior thyroid artery has limitations, however, including
reduced patch size, focal arteriosclerosis, and limited follow-up
data. Ultimately, the use of any artery is limited by its
potential for creating distal ischemia in the original locus.
Use of an endarterectomized occluded femoral artery has
been reported, which eliminated the potential for distal
ischemia71; nevertheless, this option has not become pop-
ular. However, the lessons derived in using autogenous
artery suggest that strength and compliance matching are
critical determinants for successful patch materials.
Tissue engineering, the combination of scaffolds and
cells to develop neotissues, has recently become a popular
field because the potential exists to create neotissues with
both off-the-shelf availability as well as device alterations
that can be customized to individual patient requirements.
Novel synthetic conduits formed by tissue engineering will
very likely replace structural arterial tissue after surgery. In
the late 1980s, the concept of tissue engineering grafts with
polymer scaffolds absorbed by newly replaced tissue was
reported by Langer and Vacanti.72 The first report of a
tissue-engineered conduit applied in the human vascular
system was the use of a tissue-engineered venous graft to
repair congenital defects in the pulmonary artery.73
Shin’oka et al74 used autologous bone marrow cells to seed
a scaffold copolymer of L-lactide and ε-caprolactone rein-
forced with a polyglycolic acid sleeve and reported satisfac-
tory midterm clinical results in congenital pulmonary artery
system repair. This tissue-engineered conduit has only been
used in the venous system, but has potential as an arterial
patch once its long-term strength and pathophysiologic
changes to the arterial circulation are better understood.
Specific biologic cellular approaches for tissue engi-
neering arterial grafts have started to be applied in clinical
practice, with reports of dermal fibroblasts rolled into
sheets and then used as tissue-engineered vascular
grafts.75-77 This method has focused on use of tissue-
engineered vascular grafts as arteriovenous grafts for hemo-
dialysis access and has shown fair prospects as a conduit.
The advantage of this conduit, rolled sheets of dermal
fibroblasts, for application as a carotid patch is the ability to
be tolerated within the human arterial environment, in-
cluding arterial pressure. In addition, this construct is based
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 1 Muto et al 211on autologous cells and thus is not likely to lead to rejec-
tion.
Another recent interesting approach to tissue engineer-
ing an arterial conduit has used cross-linked elastic salmon
collagen as a vascular graft.78 Although this particular con-
duit is not yet mature, the development of this graft shows
that the concepts of using only biologic material that is
gradually biodegradable and with similar wall compliance
as native vessels may ultimately lead to the development of
even better improved tissue-engineered devices.
Tissue-engineered grafts and patches still have obsta-
cles to surmount. One of the major requirements of a
tissue-engineered vascular patch is long-term stability. An-
other important requirement is to ensure a stable supply of
cells within the neotissue. If the source of the cells for a
tissue-engineered patch includes cells from middle-aged or
elderly patients, then these cells may not grow well or very
slowly, if at all. If these cells are taken from other humans or
large animals, then infection and rejection need to be
eliminated. The application of stem cells or novel types of
stem cells, such as embryonic stem or induced pluripotent
stem cells, for tissue engineered conduits has not yet been
worked out; problems with ethical issues, accurate induc-
tion of specific cell types, carcinogenic gene transduction,
and other problems still exist. For the potential of off-the-
shelf use, hybrid biomaterials such as tissue-engineered
conduits still have to surmount numerous obstacles.
CONCLUSIONS
Although minimally invasive carotid artery angioplasty
and stenting preoccupies much discussion in the treatment
of carotid artery stenosis, open surgery is still used to treat
most patients with carotid disease.4,13,79 As such, develop-
ment of carotid patches, as well as patches for use in
arteriotomy closure elsewhere, continues to remain a criti-
cal adjunct for vascular surgery. Reports comparing most
synthetic and vein patches show acceptable satisfactory
results after CEA, although problems such as infection,
rupture, handling, stroke, cost, and others, remain.
Our preference is for biologic patches such as bovine
pericardium, but we believe that the clinical results ob-
tained with most available synthetic patches are currently
similar enough to prevent clear recommendation of any
particular one. Recent novel conduits are not yet mature
enough for clinical use, although the future of biomaterials
and tissue engineered patches, especially for use as vascular
bypass grafts, is likely to be bright.
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